Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV
Jake A. Ruddy(Johns Hopkins University), Christine M. Durand(University of Maryland, Baltimore), William A. Werbel(Johns Hopkins University), Jacqueline Garonzik‐Wang(University of Wisconsin–Madison), Andrew H. Karaba(Johns Hopkins University), Justin R. Bailey(Johns Hopkins University), Brian J. Boyarsky(Johns Hopkins University), Dorry L. Segev(New York University)
Cited by 51
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Foot strike patterns and collision forces in habitually barefoot versus shod runners
|Nature|2010|1.4k
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
|American Journal of Transplantation|2017|1k